TSHA Earnings Date: Nov 3, 2026 (Estimated) — Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is TSHA's next earnings date?
Taysha Gene Therapies, Inc. (TSHA) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.13 on revenue of $755,556.
How did TSHA do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Taysha Gene Therapies, Inc. posted EPS of -$0.13 versus the -$0.11 estimate, a miss of 18.2%. Revenue was $0 against a $680,000 estimate. The stock's 1-day post-earnings move was -4.1%.
How much does TSHA stock move after earnings?
TSHA beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.3% (up or down) in the day after earnings.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.11 | -0.13 | -18.18% | $0 | ❌ Miss | -4.12% | -7.34% | -22.75% |
| 2026-05-06 | Q1 2026 | -0.10 | -0.12 | -20.00% | $0 | ❌ Miss | +0.58% | -1.30% | -15.13% |
| 2026-03-19 | Q4 2025 | -0.10 | -0.12 | -20.00% | $5.5M | ❌ Miss | +2.47% | +2.92% | +44.49% |
| 2025-11-04 | Q3 2025 | -0.09 | -0.09 | +0.00% | $0 | ➖ Inline | -4.26% | -12.78% | +0.67% |
| 2025-08-12 | Q2 2025 | -0.07 | -0.09 | -28.57% | $2.0M | ❌ Miss | +5.43% | +6.16% | +17.75% |
| 2025-02-26 | Q4 2024 | -0.08 | -0.07 | +12.50% | $2.0M | ✅ Beat | -4.71% | -4.12% | +5.88% |
| 2024-11-13 | Q3 2024 | -0.09 | -0.10 | -11.11% | $1.8M | ❌ Miss | +2.71% | -9.05% | -6.33% |
| 2024-08-12 | Q2 2024 | -0.17 | -0.09 | +47.06% | $1.1M | ✅ Beat | -2.39% | +7.66% | +9.57% |
Showing last 8 quarters.